BioCentury
ARTICLE | Financial News

GenSight gets $36M series B ahead of listing

July 24, 2015 1:13 AM UTC

Gene therapy developer GenSight Biologics S.A. (Paris, France) raised $36 million in a series B round led by Fidelity. Also participating were new investors Jennison Associates; Sphera Global HealthCare Fund; Perceptive Advisors; and HealthCap, as well as prior investors Novartis Venture Fund; Abingworth; Versant Ventures; and Index Ventures (see BioCentury, April 15, 2013).

Earlier this month, GenSight filed to raise up to $100 million through a listing of ADSs on NASDAQ underwritten by Leerink; Evercore; and Canaccord. Leerink was the placement agent for the series B. According to GenSight's prospectus, Novartis AG (NYSE:NVS; SIX:NOVN) is GenSight's largest shareholder with a 20.4% stake. Abingworth and Versant each own 17.1%, while Fidelity owns 9.4%. ...